
.
David O'Reilly PhD
Group Scientific Director
"I believe that tobacco harm reduction has the potential to be one of the biggest public health opportunities of this generation. Although the proportion of adults who smoke is likely to decline, population growth means that in 10-years time there will likely be as many or more smokers globally as there are today. We are working towards producing a range of lower-risk products for the millions of adults globally who will continue to consume tobacco and nicotine products. However, we recognise that the science is complex and that external opinion on tobacco harm reduction continues to be divided. This is why we have made a long-term commitment to build the science base needed to determine whether new products will pose reduced health risks and to seek the support and guidance of the scientific, public health and regulatory communities in this."
IIVS, which was founded in 1997, is a recognized leading provider of in vitro testing in support of toxicological safety evaluations. Rigorous scientific programmes coupled with educational and outreach initiatives have established IIVS
as a global leader in the advancement of alternatives to animal testing.

The Scientific Advisory Panel is comprised of representatives from companies and organizations eager to promote the use and acceptance of alternative methods to animal testing.
Our programme on in vitro models is detailed below.

In vitro assessment involves identifying and developing in vitro assays which model pathological processes in key smoking-related diseases. We hope these models will provide us with laboratory based data that the smoke from modified tobacco products may have a reduced biological effect.

We continue to publish our scientific research findings in peer reviewed journals. A percentage of these manuscripts are published open access. These manuscripts can be freely downloaded and viewed without subscriptions.